期刊文献+

Artemin和Ki-67在乳腺浸润性导管癌分子病理分型中的临床意义

The clinical pathological significance of Artemin and Ki-67 in moleculartype type in infiltrating ductal carcinoma of breast
下载PDF
导出
摘要 目的:探讨乳腺浸润性导管癌的临床病理分型与病理特征的关系及其对预后的影响。方法:回顾性分析2013年1月至2013年6月我院收治的287例乳腺浸润性导管癌患者病理资料。结果:乳腺浸润性导管癌患者分型:Luminal A型20例(7.0%),Luminal B型156例(54.4%),HER-2过表达型69例(24.0%),三阴型42例(14.6%);Luminal B型中HER-2阴性65例(41.7%),HER-2阳性91例(58.3%)。乳腺浸润性导管癌病理分型在患者年龄、绝经状态、病理分级、TNM分期、Artemin等因素中的分布差异明显,具有统计学意义(P<0.05)。Luminal B型乳腺癌患者多呈现病理分级高(II级以上占86.5%),分期高(II期以上占60.9%)等特点。结论:临床病理分型是针对乳腺癌个体方案治疗的重要依据,对判断预后有重要的价值。 Objective: To explore the clinic pathological characters and pathological type in breast invasive ductal carcinoma,and predict value of prognosis. Methods: Total 287 cases of breast invasive ductal carcinoma were analyzed retrospectively. Results: The cases have been divide into Luminal A,Luminal B,HER-2 over express and triple-negative. Luminal A positive in 20 cases( 7. 0%),Luminal B positive in 156 cases( 54. 4%),HER-2 over express69 cases( 24. 0%),triple-negative 42 cases( 14. 6%). In subtype of Luminal B,HER-2 positive were 91 cases( 58. 3%) and negative 65 cases( 41. 7%). The subtype of breast invasive ductal carcinoma was associated with age,menopausal status,pathological grade,TNM stage,and protein artemin( P〈0. 05). Most of Luminal B was later in grade( 86. 5% cases were more than II grade) and stage( 60. 9% cases were more than II stage). Conclusion: Clinical pathological type is important for individual therapy for breast invasive ductal carcinoma and have great value for prognosis.
出处 《现代肿瘤医学》 CAS 2016年第8期1210-1213,共4页 Journal of Modern Oncology
关键词 乳腺肿瘤 浸润性导管癌 分子分型 病理 breast neoplasm invasive ductal carcinoma molecular subtype pathology
  • 相关文献

参考文献4

二级参考文献49

  • 1李秀娟,廖琪,孙中华,郝明.Ki67和Survivin在卵巢上皮性癌中的表达及意义[J].中国全科医学,2009,12(16):1534-1535. 被引量:10
  • 2何振宇,李彪,胡英,管迅行.Ki67在乳腺癌组织中的表达及临床病理分析[J].中国初级卫生保健,2005,19(12):94-95. 被引量:16
  • 3赵延龙,陈江,姜汉国.Survivin、p53基因在甲状腺乳头状癌组织中表达的研究[J].哈尔滨医科大学学报,2006,40(1):23-26. 被引量:9
  • 4王立芝,薛龙,谭冬梅,谭毅.Survivin的研究进展[J].医学综述,2006,12(18):1089-1092. 被引量:8
  • 5龚西驗,丁华野.乳腺病理学[M].北京:人民卫生出版社,2009:375 -7.
  • 6Calascibetta A, Cabibi D, Rausa L, et al.Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients [J] . Nucleosides Nucleotides Nucleic Acids, 2006, 25 (9111) : 1193-1196.
  • 7Masuda H, Masuda N, Kodama Y, et al.Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients [J]. Cancer Chemother Pharmacol, 2011 , 67 (4) : 911-917.
  • 8Faneyte IF, Schrama JG, Peterse JL, et al.Breast cancer resp"nse to neoadjuvant chemotherapy: predictive markers and relation with outcome [J]. Br J Cancer, 2003, 88 (3) : 406-412.
  • 9Zhao H, Ho PC, Lo YH, et al.Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer [J]. PLoS One, 2012,7(1): e29416.
  • 10NCCN乳腺癌专家组.NCCN乳腺癌临床实践指南(中国版)[S].北京:NCCN乳腺癌临床实践指南(中国版)讨论组,2011.

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部